The governance reforms enacted in late 2025 have established a highly disciplined, efficient capital allocation framework at Medtronic. Under the oversight of the Growth and Operating Committees, corporate leadership has successfully transitioned from a period of operational consolidation to an offensive M&A posture. The acquisitions of CathWorks, Scientia Vascular, and SPR Therapeutics demonstrate this strategic alignment, targeting high-growth, minimally invasive, and softw